Suicidal Ideation in Medicinal Cannabis Patients: A 12-Month Prospective Study.

IF 2.5 3区医学 Q2 PSYCHIATRY Archives of Suicide Research Pub Date : 2024-07-24 DOI:10.1080/13811118.2024.2356615

M T Lynskey, H Thurgur, A Athanasiou-Fragkouli, A K Schlag, D J Nutt

{"title":"Suicidal Ideation in Medicinal Cannabis Patients: A 12-Month Prospective Study.","authors":"M T Lynskey, H Thurgur, A Athanasiou-Fragkouli, A K Schlag, D J Nutt","doi":"10.1080/13811118.2024.2356615","DOIUrl":null,"url":null,"abstract":"Objective: To document the prevalence and correlates of suicidal ideation (SI) among individuals seeking cannabis-based medicinal products (CBMPs); to test whether SI declines or intensifies after three months of CBMP treatment and to document 12-month trajectories of depression in those reporting SI and other patients.Method: Observational data were available for 3781 patients at entry to treatment, 2112 at three months and 777 for 12 months. Self-reported depressed mood and SI were assessed using items from the PHQ-9. Additional data included sociodemographic characteristics and self-reported well-being.Results: 25% of the sample reported SI at treatment entry and those with SI had higher levels of depressed mood (mean = 17.4 vs. 11.3; F(1,3533) = 716.5, p < .001) and disturbed sleep (mean = 13.8 vs. 12.2, F(1,3533) = 125.9, p < .001), poorer general health (mean = 43.6 vs. 52.2, F(1,3533) = 118.3, p < .001) and lower quality of life (mean = 0.44 vs. 0.56 (F(1,3533) = 118.3, p < .001). The prevalence of SI reduced from 23.6% to 17.6% (z = 6.5, p < .001) at 3 months. Twelve-month follow-up indicated a substantial reduction in depressed mood with this reduction being more pronounced in those reporting SI (mean (baseline) = 17.7 vs. mean (12 months) = 10.3) than in other patients (mean (baseline) = 11.1 vs. mean (12 months) = 7.0).Conclusions: SI is common among individuals seeking CBMPs to treat a range of chronic conditions and is associated with higher levels of depressed mood and poorer quality of life. Treatment with CBMPs reduced the prevalence and intensity of suicidal ideation.","PeriodicalId":8325,"journal":{"name":"Archives of Suicide Research","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Suicide Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13811118.2024.2356615","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To document the prevalence and correlates of suicidal ideation (SI) among individuals seeking cannabis-based medicinal products (CBMPs); to test whether SI declines or intensifies after three months of CBMP treatment and to document 12-month trajectories of depression in those reporting SI and other patients.

Method: Observational data were available for 3781 patients at entry to treatment, 2112 at three months and 777 for 12 months. Self-reported depressed mood and SI were assessed using items from the PHQ-9. Additional data included sociodemographic characteristics and self-reported well-being.

Results: 25% of the sample reported SI at treatment entry and those with SI had higher levels of depressed mood (mean = 17.4 vs. 11.3; F_(1,3533) = 716.5, p < .001) and disturbed sleep (mean = 13.8 vs. 12.2, F_(1,3533) = 125.9, p < .001), poorer general health (mean = 43.6 vs. 52.2, F_(1,3533) = 118.3, p < .001) and lower quality of life (mean = 0.44 vs. 0.56 (F_(1,3533) = 118.3, p < .001). The prevalence of SI reduced from 23.6% to 17.6% (z = 6.5, p < .001) at 3 months. Twelve-month follow-up indicated a substantial reduction in depressed mood with this reduction being more pronounced in those reporting SI (mean _(baseline) = 17.7 vs. mean (12 months) = 10.3) than in other patients (mean _(baseline) = 11.1 vs. mean _{(12 months)} = 7.0).

Conclusions: SI is common among individuals seeking CBMPs to treat a range of chronic conditions and is associated with higher levels of depressed mood and poorer quality of life. Treatment with CBMPs reduced the prevalence and intensity of suicidal ideation.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

药用大麻患者的自杀意念：为期 12 个月的前瞻性研究。

目的记录寻求大麻药用产品（CBMPs）治疗的患者中自杀意念（SI）的发生率和相关性；检验 CBMP 治疗三个月后自杀意念是否会减弱或增强，并记录报告有自杀意念的患者和其他患者 12 个月的抑郁轨迹：我们获得了 3 781 名患者的观察数据，这些患者在开始治疗时有 2 112 人，治疗三个月后有 2 112 人，治疗 12 个月后有 777 人。使用 PHQ-9 中的项目对患者自我报告的抑郁情绪和 SI 进行评估。其他数据包括社会人口学特征和自我报告的幸福感。结果：25% 的样本在开始治疗时报告了 SI，有 SI 的患者抑郁情绪水平更高（平均值 = 17.4 vs. 11.3；F(1,3533) = 716.5，p < .001）和睡眠紊乱（平均值 = 13.8 vs. 12.2，F(1,3533) = 125.9，p < .001），一般健康状况较差（平均值 = 43.6 vs. 52.2，F(1,3533) = 118.3，p < .001），生活质量较低（平均值 = 0.44 vs. 0.56，F(1,3533) = 118.3，p < .001）。3 个月后，SI 患病率从 23.6% 降至 17.6%（z = 6.5，p < .001）。12 个月的随访表明，抑郁情绪大幅下降，报告 SI 的患者（平均（基线）= 17.7 vs. 平均（12 个月）= 10.3）比其他患者（平均（基线）= 11.1 vs. 平均（12 个月）= 7.0）的抑郁情绪下降更为明显：在寻求 CBMP 治疗一系列慢性疾病的患者中，SI 很常见，并且与较高程度的抑郁情绪和较差的生活质量有关。CBMPs治疗降低了自杀意念的发生率和强度。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Archives of Suicide Research Multiple-

CiteScore

6.10

自引率

7.10%

发文量

期刊介绍： Archives of Suicide Research, the official journal of the International Academy of Suicide Research (IASR), is the international journal in the field of suicidology. The journal features original, refereed contributions on the study of suicide, suicidal behavior, its causes and effects, and techniques for prevention. The journal incorporates research-based and theoretical articles contributed by a diverse range of authors interested in investigating the biological, pharmacological, psychiatric, psychological, and sociological aspects of suicide.